Acutus Medical Initiates First IDE Therapy Trial With AcQBlate Force Sensing Ablation System The Acutus Medical AcQBlate Force sensing ablation catheter. April 5, 2021 — Acutus Medical today announced initial U.S. enrollments in the company’s AcQForce Flutter Investigational Device Exemption (IDE) clinical trial. This trial is expected to enroll up to 150 subjects in leading centers globally and will evaluate the safety and efficacy of the AcQBlate Force sensing ablation catheter and system in the treatment of right atrial typical flutter. In the U.S., right atrial typical flutter ablation procedures currently account for approximately 30% of cardiac ablations and are expected to reach 200,000 annually by 2025.[1]